Entospletinib,Lanraplenib
Kronos Bio,gilead
[]
$kron kronos bio continues to advance investigational syk inhibitors entospletinib and lanraplenib with new preclinical data at eha2022 congress 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities